"10.1371_journal.pone.0075010","plos one","2013-09-12T00:00:00Z","Tomoyo Sasaki; Hyosook Hwang; Cu Nguyen; Robert A Kloner; Michael Kahn","Department of Biochemistry and Molecular Biology, Keck School of Medicine of University of Southern California, Los Angeles, California, United States of America; The Heart Institute, Good Samaritan Hospital, Los Angeles, California, United States of America; Division of Cardiovascular Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California, United States of America; Norris Comprehensive Cancer Research Center, University of Southern California, Los Angeles, California, United States of America; Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, Republic of Korea","Conceived and designed the experiments: RK MK. Performed the experiments: TS HH CN. Analyzed the data: TS HH RK MK. Wrote the paper: TS HH RK MK.","Dr. Kahn is a consultant, and equity holder in Prism Biolab, which is developing the CBP/beta-catenin antagonist PRI-724.","2013","09","Tomoyo Sasaki","TS",5,TRUE,2,3,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
